Pablo Przygoda

Pablo Przygoda, MD, is the Head of Medical Affairs at QED Therapeutics, leading efforts to develop and launch Infigratinib for achondroplasia and hypochondroplasia since January 2025. Prior to this role, Pablo served as Principal Consultant at Medical Affairs Solutions, LLC, and Vice President of Medical Affairs at BeyondSpring, where leadership encompassed global medical initiatives for oncology and innovative treatments for chemotherapy-induced neutropenia and non-small cell lung cancer. Previously held roles include Sr. Director of Global Medical Affairs at Alexion Pharmaceuticals, Global Medical Lead at Shire Pharmaceuticals, Global Medical Affairs Lead at Sanofi, and Senior Associate Director at Boehringer Ingelheim. Pablo earned an MBA in Business Administration from Duke University and a medical degree from Universidad Hospital Italiano de Buenos Aires.